Wittmann David, Paulson Eric S, Banerjee Anjishnu, Banla Leou Ismael, Schultz Christopher, Awan Musaddiq, Chen Xinfeng, Omari Eenas A, Straza Michael, Li X Allen, Erickson Beth, Hall William A
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
Adv Radiat Oncol. 2025 Apr 11;10(5):101758. doi: 10.1016/j.adro.2025.101758. eCollection 2025 May.
Patients receiving adaptive magnetic resonance guided radiation therapy (MRgRT) undergo contour modification prior to treatment delivery, which takes 15 to over 60 minutes. We hypothesized that during the time required to create an adaptive MRgRT plan, organ movement will result in dosimetric changes to regional organs at risk (OARs). This study quantifies the dosimetric impact of OAR motion during the time required to perform adaptive MRgRT.
Thirty-one patients with pancreatic adenocarcinoma, prostate adenocarcinoma, hepatocellular carcinoma, and oligo-metastases who received MRgRT using a 1.5 Tesla MR-Linac were prospectively enrolled in an open registry imaging trial (NCT03500081). Two magnetic resonance imaging (MRI) studies were acquired predelivery for each MRgRT treatment fraction: an initial "pretreatment" MRI (input to the adaptive evaluation with or without recontouring and replanning process), and a second "verification MRI" (acquired after the recontouring and adaption process and immediately before treatment delivery or "beam-on"). On the verification MRI, normal organs were recontoured offline. Recontoured normal organs included the colon, duodenum, small bowel, and stomach. Differences in OARs between organ positions represented the normal organ movement during the time required for plan adaption. Maximum dose (Dmax), volumetric (V) 0.5 cubic centimeter dose (D0.5cc), 3000 cGy (V30), and 2000 cGy (V20) were calculated from the recontoured verification MRI.
Differences in Dmax, per fraction, for the listed normal organs were as follows: colon/rectum 239.50 cGy ( = .09), duodenum 136.40 cGy ( = .05), small bowel 488.27 cGy ( < .01), and stomach 95.92 ( = .17). Small bowel demonstrated a significant difference in Dmax, D0.5cc, and V30.
Statistically significant differences in small bowel doses are demonstrated as a result of motion during the timing required for adaptive MRgRT. These results reflect the importance of verifying MRI acquisition during adaptive MRgRT to confirm the location of OARs. They also identify the necessity of strategies to account for the dynamic nature of regional OARs.
接受自适应磁共振引导放射治疗(MRgRT)的患者在治疗实施前需进行轮廓修正,这一过程需要15至60多分钟。我们推测,在创建自适应MRgRT计划所需的时间内,器官运动会导致区域危及器官(OARs)的剂量学变化。本研究量化了在进行自适应MRgRT所需时间内OAR运动的剂量学影响。
31例患有胰腺腺癌、前列腺腺癌、肝细胞癌和寡转移的患者,使用1.5特斯拉MR直线加速器接受MRgRT,前瞻性纳入一项开放注册成像试验(NCT03500081)。对于每个MRgRT治疗分次,在治疗前采集两次磁共振成像(MRI)研究:一次初始的“治疗前”MRI(输入到有或无重新轮廓描绘和重新计划过程的自适应评估中),以及第二次“验证MRI”(在重新轮廓描绘和自适应过程之后且在治疗实施前或“射束开启”前立即采集)。在验证MRI上,对正常器官进行离线重新轮廓描绘。重新轮廓描绘的正常器官包括结肠、十二指肠、小肠和胃。器官位置之间的OAR差异代表了计划自适应所需时间内的正常器官运动。根据重新轮廓描绘的验证MRI计算最大剂量(Dmax)、体积(V)0.5立方厘米剂量(D0.5cc)、3000 cGy(V30)和2000 cGy(V20)。
所列正常器官每分次的Dmax差异如下:结肠/直肠239.50 cGy(P = 0.09),十二指肠136.40 cGy(P = 0.05),小肠488.27 cGy(P < 0.01),胃95.92(P = 0.17)。小肠在Dmax、D0.5cc和V30方面显示出显著差异。
在自适应MRgRT所需时间内,由于运动,小肠剂量存在统计学显著差异。这些结果反映了在自适应MRgRT期间验证MRI采集以确认OAR位置的重要性。它们还确定了应对区域OAR动态特性的策略的必要性。